Monoamine oxidase A (MAOA) is an enzyme involved in the metabolism of the monoamines, eg 5-HT and noradrenaline. It converts the monoamines into their corresponding carboxylic acid via an aldehyde intermediate. MAOA regulates both the free intraneuronal concentration and the releasable stores of 5-HT and noradrenaline. MAOA inhibitors bind to and inhibit MAOA, preventing monoamine degradation. This results in greater stores of monoamines available for release. MAOA inhibitors are used in the treatment of depression. It has been proposed that MAO inhibitors treat depression by preventing monoamine degradation and delaying downregulation of beta-andrenoceptors and 5-HT2 receptors.
Click here: Discover the role of MAO-A inhibitors in depression treatment
Related content
Patients with bipolar disorder and comorbidities are typically more complex cases than those without medical or psychiatric comorbidities
Factors associated with mixed features includes unemployment among others
In this video, Professors Lakshmi Yatham, MD., and Christoph Correll, MD. discuss the challenges of differentiating bipolar disorder.